×
About 5,768 results

ALLMedicine™ Portal Hypertension Center

Research & Reviews  2,088 results

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PORTAL HYPERTENSION.
https://doi.org/10.1016/j.clinre.2021.101767
Clinics and Research in Hepatology and Gastroenterology; Thabut D, Weil D et. al.

Aug 1st, 2021 - Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient...

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY BILIARY CHOLANGITIS.
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts (1). It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

Transjugular intrahepatic porto-systemic shunts in the setting of portal vein thrombosi...
https://doi.org/10.1111/1751-2980.13035
Journal of Digestive Diseases; Yeoh SW, Kok HK

Jul 30th, 2021 - The presence of portal venous thrombosis (PVT) has previously been considered a contraindication to the insertion of transjugular intrahepatic porto-systemic shunts (TIPSS). However, patients with PVT may be symptomatic with complications of porta...

Safety, Feasibility, Yield, Diagnostic and Prognostic Implications of Transjugular Live...
https://doi.org/10.1097/MPG.0000000000003249
Journal of Pediatric Gastroenterology and Nutrition; Lal BB, Sood V et. al.

Jul 27th, 2021 - The objectives of the study were to evaluate the indications, feasibility, complications and clinical implications of transjugular liver biopsy (TJLB) in children. Data of all TJLB performed in children less than 18 years old was retrieved from th...

Impact of vascular liver disease on the menstrual cycle and metabolic status in premeno...
https://doi.org/10.1016/j.clinre.2021.101756
Clinics and Research in Hepatology and Gastroenterology; Stempak-Droissart T, Rousset-Jablonski C et. al.

Jul 25th, 2021 - Vascular liver disease (VLD) are rare liver diseases, which affect women at reproductive ages. Main complications are bleeding (portal hypertension, thrombopenia or anticoagulation related) and thromboembolism. Failure of liver function can occur....

see more →

Guidelines  8 results

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PORTAL HYPERTENSION.
https://doi.org/10.1016/j.clinre.2021.101767
Clinics and Research in Hepatology and Gastroenterology; Thabut D, Weil D et. al.

Aug 1st, 2021 - Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient...

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY BILIARY CHOLANGITIS.
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts (1). It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

ACR Appropriateness Criteria® Radiologic Management of Portal Hypertension.
https://doi.org/10.1016/j.jacr.2021.02.013
Journal of the American College of Radiology : JACR; , Pinchot JW et. al.

May 8th, 2021 - Cirrhosis is a heterogeneous disease that cannot be studied as a single entity and is classified in two main prognostic stages: compensated and decompensated cirrhosis. Portal hypertension, characterized by a pathological increase of the portal pr...

AGA Clinical Practice Update on Management of Bleeding Gastric Varices: Expert Review.
https://doi.org/10.1016/j.cgh.2021.01.027
Clinical Gastroenterology and Hepatology : the Official C... Henry Z, Patel K et. al.

Jan 26th, 2021 - Management of bleeding gastric varices (GV) presents a unique challenge for patients with portal hypertension. Despite over thirty years of diagnostic and treatment advances standardized practices for bleeding GV are lacking and unsupported by ade...

Transjugular intrahepatic portosystemic stent-shunt in the management of portal hyperte...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306985
Gut Tripathi D, Stanley AJ et. al.

Mar 3rd, 2020 - These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  113 results

Natural History of Noncirrhotic Portal Hypertension
https://clinicaltrials.gov/ct2/show/NCT02417740

Apr 13th, 2020 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis
https://clinicaltrials.gov/ct2/show/NCT03654053

Apr 6th, 2020 - HMG-coA reductase inhibitors (statins), independent of cholesterol-lowering effects, are beneficial in liver diseases by reducing endothelial dysfunction, intrahepatic vasoconstriction, inflammation and fibrosis, and can reduce portal vein blood p...

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
https://clinicaltrials.gov/ct2/show/NCT02555111

Mar 10th, 2020 - Chronic portal vein thrombosis (PVT) is a rare disease, affecting young patients, characterized by permanent obstruction of the portal vein trunk causing portal hypertension. In 60-70% of cases it is related to high risk, moderate or mild prothrom...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Feb 28th, 2020 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

The Clinical Significance of Portal Hypertension After Cardiac Surgery: a Multicenter Prospective Observational Study
https://clinicaltrials.gov/ct2/show/NCT03656263

Feb 20th, 2020 - Hypothesis: Portal flow pulsatility detected by Doppler ultrasound during cardiac surgery is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse clinical outcomes. Background: Peri...

see more →

News  93 results

Ocaliva (obeticholic acid) by Intercept Pharmaceuticals: Drug Safety Communication - Due to Risk of Serious Liver Injury, FDA Restricts Use of Ocaliva in Primary Biliary Cholangitis Patients with A...
https://www.fda.gov/safety/medical-product-safety-information/ocaliva-obeticholic-acid-intercept-pharmaceuticals-drug-safety-communication-due-risk-serious-liver

[Posted 05/26/2021]  AUDIENCE: Patient, Health Professional, Pharmacy    ISSUE: The FDA is restricting the use of the liver disease medicine Ocaliva (obeticholic acid) in patients having primary biliary cholangitis (PBC) with advanced cirrhosis of...

Patients With Decompensated Cirrhosis Often Lack Advance Care Plans
https://www.medscape.com/viewarticle/947552

Mar 17th, 2021 - (Reuters Health) - Many patients with decompensated cirrhosis do not have advance care plans in place to cover their trajectory of illness through end-of-life care, according to a new study that concludes this may be one reason they receive overly...

AGA Clinical Practice Update: Bariatric Surgery in Patients With Cirrhosis
https://www.medscape.com/viewarticle/945465

Feb 8th, 2021 - Obesity, a risk factor for nonalcoholic fatty liver disease (NAFLD) and a prevalent comorbidity among people with cirrhosis of all etiologies, is associated with a number of untoward health outcomes, and weight loss is an important goal, according...

Rifaximin May Prevent Hepatic Encephalopathy After TIPS Placement for Cirrhosis
https://www.medscape.com/viewarticle/945312

Feb 5th, 2021 - NEW YORK (Reuters Health) - The antibiotic rifaximin given before and after transjugular intrahepatic portosystemic shunt (TIPS) placement helped prevent hepatic encephalopathy (HE) in a placebo-controlled trial. "TIPS is a very effective treatmen...

AASLD 2020: A Clinical News Roundup
https://www.medscape.com/viewarticle/941739

Nov 30th, 2020 - Studies that address fundamental questions in hepatology and have the potential to change or improve clinical practice were the focus of a clinical debrief session from the virtual annual meeting of the American Association for the Study of Liver ...

see more →

Patient Education  3 results see all →